Mohammad Ali Khaksar

Dr. Mohammad Ali Khaksar

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Toxicologie Analytique et Clinique
Verified
Journal Article
Closed access
RAReza Nozari Asl
Reza Nozari Asl
Neamatollah JaafarzadehNeamatollah Jaafarzadeh
Neamatollah Jaafarzadeh
FJFaezeh Jahedi
Faezeh Jahedi
MKMohammad Ali Khaksar
Mohammad Ali Khaksar
BSBamshad Shenavar
Bamshad Shenavar

13 September 2025 in Cancer Reports
Verified
Journal Article
Open access
MAMojtaba Aghaei
Mojtaba Aghaei
MJMohammad Ali JalaliFar
Mohammad Ali JalaliFar
AAarshid yousefi avarvand
arshid yousefi avarvand
SBSeyed Sobhan Bahreiny
Seyed Sobhan Bahreiny
NKNegin Karamali
Negin Karamali
EBEbrahim Babadi
Ebrahim Babadi
Background: Vascular endothelial growth factor‐A (VEGF‐A), In combination with other pro‐angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).Aims: This meta‐analysis aims to evaluate the diagnostic value of VEGF‐A and its prognostic relevance in the outcome of patients with ALL.Methods and Results: A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random‐effects model to quantify effect sizes. Subgroup analyses and meta‐regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF‐A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; p = 0.004). Notably, increased VEGF‐A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; p = 0.010).Conclusion: The results indicate that heightened VEGF‐A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.

19 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMohammad Ali Khaksar
Mohammad Ali Khaksar
IEIslam Eljilany
Islam Eljilany
IYIbrahim Yassine
Ibrahim Yassine
XYXiaoqing Yu
Xiaoqing Yu
JTJamie K. Teer
Jamie K. Teer
ATAhmad Tarhini
Ahmad Tarhini
Background: Identifying patients most likely to benefit from immune checkpoint inhibitors (ICIs) remains a significant challenge in advanced melanoma. We evaluated the association between tumor somatic mutations and clinical outcomes, focusing on relapse-free survival (RFS) and overall survival (OS) in locoregionally advanced melanoma patients treated with neoadjuvant ipilimumab. Methods: Tumor specimens and matched peripheral blood samples from 22 patients underwent whole-exome sequencing (WES) to identify non-synonymous somatic mutations. Tumor mutational burden (TMB) was quantified, and specific mutations were analyzed for associations with survival outcomes. Results: The analysis revealed a mutational landscape dominated by single-nucleotide missense mutations with a median TMB of 11.4 mutations/MB. BRAF and NRAS mutations were detected in 73% of patients and exhibited mutual exclusivity and concurrence patterns (p < 0.05). Positional clustering identified NRAS and SLC35B4 as key contributors to melanoma (FDR p-value < 0.05). Log-rank analysis indicated that mutations in ODZ1, USP34, CEP192, EML5, KIAA1797, ATAD5, and ANKHD1–EIF4EBP were associated with shorter survival outcomes (RFS or OS). The associations remained significant in both univariate and multivariable Cox regression models adjusted for TMB. These genes can be broadly grouped into functional categories relevant to tumor progression and immune modulation. In applying multiple testing correction, none maintained statistical significance, indicating that these findings should be interpreted as exploratory and require validation in independent cohorts. Conclusions: This study identified tumor genomic alterations associated with clinical outcomes in melanoma patients treated with neoadjuvant ipilimumab, suggesting their potential role in anti-tumor immunity. These findings warrant further investigation in larger cohorts and across other ICIs in melanoma and other malignancies.

11 August 2026 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
SSShokouh Shayanpour
Shokouh Shayanpour
MRmaryam radan
maryam radan
ZMZahra Mansouri
Zahra Mansouri
MKMohammad Ali Khaksar
Mohammad Ali Khaksar
PRParisa Rashidi
Parisa Rashidi
SSShokouh of Shayanpour
Shokouh of Shayanpour
Bisphenol A (BPA) is an environmental toxicant known to induce nephrotoxicity primarily through oxidative stress–mediated inflammation and apoptosis.